Source: Annual Congress 2011 - Treatment of tuberculosis and adverse drug reactions
Disease area: Respiratory infections



Rating:

Share or cite this content

Citations should be made in the following way:
J. Ben Amar, B. Dhari, L. El Gharbi, M. A. Baccar, S. Azzabi, H. Aouina, H. Bouacha (Tunis, Tunisia). Severe adverse effects of antitubercular drugs and patient management. Eur Respir J 2011; 38: Suppl. 55, 4405

Member's Comments

No comment yet.

Related content which might interest you: Adverse effects of anti-tuberculosis drugs in hemodialysis patients Source: International Congress 2019 – Tuberculosis and comorbidities Year: 2019 Management of adverse drug events in TB therapy Source: Eur Respir Mon 2012; 58: 167-193 Year: 2012 Adverse anti-tuberculosis drug events and their management Source: Eur Respir Monogr 2018; 82: 205-227 Year: 2018 Monitoring of antituberculous drugs adverse events during the treatment of multidrug-resistant pulmonary tuberculosis Source: Annual Congress 2011 - Treatment of tuberculosis and adverse drug reactions Year: 2011 Adverse effects analysis results during anti-TB treatment among hemodialysis patients Source: Virtual Congress 2021 – Challenges and advances in the diagnosis and clinical management of tuberculosis Year: 2021 Cardiovascular adverse effects during itraconazole therapy Source: Eur Respir J 2008; 32: 240 Year: 2008 The safety of LAMA/LABA combination therapy for the ocular and urinary adverse effects in the COPD patients Source: International Congress 2019 – COPD clinical trials: inhaled and oral therapies Year: 2019 Can toxicities induced by antituberculosis drugs be better managed in diabetic patients? Source: Eur Respir J, 50 (1) 1700409; 10.1183/13993003.00409-2017 Year: 2017 Experimental justification choise to prevent hepatotoxic reactions to anti-TB drugs based on gene-phenotypic characteristics Source: International Congress 2019 – Tuberculosis: diagnosis Year: 2019 Adverse effects of second-line drugs during the treatment of multidrug resistant tuberculosis patients Source: Eur Respir J 2005; 26: Suppl. 49, 650s Year: 2005 Frequent adverse events during prolonged Bedaquiline treatment on XDR-tuberculosis patients Source: International Congress 2019 – Tuberculosis and non-TB mycobacterial infection II Year: 2019 Low-dose amiodarone therapy may be responsible of serious adverse pulmonary effects in patients without pre-existing lung disease Source: Eur Respir J 2004; 24: Suppl. 48, 280s Year: 2004 The cost-efficacy of combined anti-inflammatory therapy in the treatment of children in severe persistent asthma Source: Eur Respir J 2003; 22: Suppl. 45, 134s Year: 2003 The side-effects of TB therapy: myth and reality Source: Annual Congress 2005 - PG10 - The management of tuberculosis: tradition and novelties Year: 2005 Noncompliance on antituberculosis treatment and the psychological profile Source: Eur Respir J 2001; 18: Suppl. 33, 467s Year: 2001 The nephrotoxic effect assesment of tuberculostatic drugs therapy by urinary enzymes Source: Eur Respir J 2004; 24: Suppl. 48, 654s Year: 2004 Predictors of hepatotoxicity among patients with tuberculosis treated with antituberculous medication Source: International Congress 2016 – Tuberculosis: the elderly, the diabetic, the unusual, and the severe Year: 2016 Late Breaking Abstract - The outcome of COVID-19 in interstitial lung disease patients treated with anti-inflammatory drugs and antiviral drugs Source: Virtual Congress 2021 – Prognostic markers of disease progression in non-idiopathic pulmonary fibrosis interstitial lung diseases Year: 2021 Manifestations of hypersensitivity to anti-tuberculosis drugs Source: International Congress 2018 – Challenges in tuberculosis care Year: 2018